VEGFA and glioblastoma: However, in addition to the inherent disadvantages offered by their systemic administration, anti-VEGF agents also promoted the GBM tumor escape and induced tumor invasion (Kunkel et al., 2001; Lucio-Eterovic et al., 2009).